Kevin Kai Hill

Array ( [id] => 16206920 [patent_doc_number] => 20200239910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => METHODS AND COMPOSITIONS FOR PREPARING GENETICALLY ENGINEERED CELLS [patent_app_type] => utility [patent_app_number] => 16/637447 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -85 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072827 [patent_doc_number] => 20190085301 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => RECOMBINANT AAVS HAVING USEFUL TRANSCYTOSIS PROPERTIES [patent_app_type] => utility [patent_app_number] => 16/058938 [patent_app_country] => US [patent_app_date] => 2018-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17470 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16058938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13586657 [patent_doc_number] => 20180344877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/058808 [patent_app_country] => US [patent_app_date] => 2018-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16058808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622877 [patent_doc_number] => 20180362990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => THERAPEUTIC [patent_app_type] => utility [patent_app_number] => 16/057897 [patent_app_country] => US [patent_app_date] => 2018-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24545 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16057897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14649379 [patent_doc_number] => 20190231818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => IMMUNE EFFECTOR CELLS PRE-INFECTED WITH ONCOLYTIC VIRUS [patent_app_type] => utility [patent_app_number] => 16/056152 [patent_app_country] => US [patent_app_date] => 2018-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16056152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16498366 [patent_doc_number] => 10863729 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-15 [patent_title] => Rodents having a humanized [patent_app_type] => utility [patent_app_number] => 16/052700 [patent_app_country] => US [patent_app_date] => 2018-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 13 [patent_no_of_words] => 16014 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16052700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929077 [patent_doc_number] => 20190048054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => Mesenchymal Stem Cells Expressing Biomarkers that Predict the Effectiveness of Mesenchymal Stem Cells for Treating Diseases and Disorders [patent_app_type] => utility [patent_app_number] => 16/045978 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16045978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13552427 [patent_doc_number] => 20180327761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => METHOD FOR PRODUCING PRECISE DNA CLEAVAGE USING CAS9 NICKASE ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/045602 [patent_app_country] => US [patent_app_date] => 2018-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9176 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16045602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15927955 [patent_doc_number] => 20200155611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING ADDICTIONS [patent_app_type] => utility [patent_app_number] => 16/631861 [patent_app_country] => US [patent_app_date] => 2018-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16631861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15994117 [patent_doc_number] => 20200172929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => GENE THERAPY FOR OCULAR DISORDERS [patent_app_type] => utility [patent_app_number] => 16/621627 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16621627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19778716 [patent_doc_number] => 12227740 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => CBLB endonuclease variants, compositions, and methods of use [patent_app_type] => utility [patent_app_number] => 16/616713 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 13 [patent_no_of_words] => 47472 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18399454 [patent_doc_number] => 11661581 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-30 [patent_title] => Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells [patent_app_type] => utility [patent_app_number] => 15/988643 [patent_app_country] => US [patent_app_date] => 2018-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 20 [patent_no_of_words] => 17234 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15988643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14372415 [patent_doc_number] => 20190160120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => DNA, METHODS ETC [patent_app_type] => utility [patent_app_number] => 15/985658 [patent_app_country] => US [patent_app_date] => 2018-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15985658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19105806 [patent_doc_number] => 11958887 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Gene therapy for tuberous sclerosis [patent_app_type] => utility [patent_app_number] => 16/613907 [patent_app_country] => US [patent_app_date] => 2018-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 20 [patent_no_of_words] => 13264 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13424751 [patent_doc_number] => 20180263918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => ENCAPSULATION OF MESSENGER RNA [patent_app_type] => utility [patent_app_number] => 15/979054 [patent_app_country] => US [patent_app_date] => 2018-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15979054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512961 [patent_doc_number] => 20200392219 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => EXTRACELLULAR VESICLES COMPRISING MEMBRANE-TETHERED TGF-BETA, COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/611099 [patent_app_country] => US [patent_app_date] => 2018-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36754 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15556817 [patent_doc_number] => 20200062820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => Method for Treating Ischemic Tissue [patent_app_type] => utility [patent_app_number] => 16/610029 [patent_app_country] => US [patent_app_date] => 2018-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16610029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13428605 [patent_doc_number] => 20180265845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE [patent_app_type] => utility [patent_app_number] => 15/964423 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15964423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413699 [patent_doc_number] => 20180258392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE [patent_app_type] => utility [patent_app_number] => 15/964446 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34734 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15964446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13508249 [patent_doc_number] => 20180305667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERS [patent_app_type] => utility [patent_app_number] => 15/959085 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44748 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15959085 [rel_patent_id] =>[rel_patent_doc_number] =>)